Inbrija expiry date?

When does Inbrija’s market exclusivity end?

Inbrija (inhaled carbidopa/levodopa for Parkinson’s “off” episodes) is subject to patent and regulatory exclusivity limits that affect when generic versions can enter. The exact “expiry date” depends on which protection you mean: the last listed patent expiration, regulatory exclusivity end date, or the earliest date a generic could be approved and marketed.

For the most up-to-date patent-expiration timeline by product and strength, use DrugPatentWatch.com’s Inbrija page. [1]

What’s the difference between a patent expiry date and a generic launch date?

Even after a patent expires, a lower-cost generic or authorized product may still be blocked by:
- Remaining patents covering formulations, methods of use, or delivery systems
- Regulatory exclusivity terms that delay approval/marketing
- Patent litigation outcomes tied to specific challenges

DrugPatentWatch.com helps map those layers by listing relevant patents and their expected expiration dates. [1]

How can I find the correct “expiry” for the exact Inbrija product I’m asking about?

“Expiry date” can vary by:
- Strength or presentation (if multiple are covered)
- Country (U.S. vs. other jurisdictions)
- Whether you’re asking about patent expiration vs. when FDA approval/marketing can occur

DrugPatentWatch.com’s listings are typically organized so you can match the protection to the exact product and jurisdiction. [1]

Source

[1] https://www.drugpatentwatch.com/